DB
BDTX icon

Dmitry Balyasny’s Black Diamond Therapeutics BDTX Stock Holding History

Dmitry Balyasny’s Portfolio BDTX Stock Details BDTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1M Buy
542,172
+31,361
+6% +$76.7K ﹤0.01% 2207
2026
Q1 		$1.09M Buy
+510,811
New +$1.21M ﹤0.01% 2044
2024
Q2 		– Sell
-34,921
Closed -$177K – 2588
2024
Q1 		$177K Buy
+34,921
New +$141K ﹤0.01% 2434
2021
Q2 		– Sell
-28,448
Closed -$690K – 1963
2021
Q1 		$690K Buy
+28,448
New +$767K ﹤0.01% 1339

Other funds holding BDTX

NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
DCM
Defilade Capital Management Emeryville, California $747M AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Connor, Clark & Lunn Investment Management (CC&L)
Connor, Clark & Lunn Investment Management (CC&L) Vancouver, British Columbia, Canada $52.8B AUM 58.98% 1-Year Est. Return

Dmitry Balyasny's BDTX Position: Q2 2026 in Review

Dmitry Balyasny increased its Black Diamond Therapeutics (BDTX) stake by 6.1% in Q2 2026, buying an estimated $76.7K and bringing the position to 542,172 shares worth $1M. The position accounts for ﹤0.01% of the portfolio, ranked #2207.

Dmitry Balyasny first reported a position in BDTX in Q1 2021 and has held it in 4 quarters since. The position peaked at $1.09M in Q1 2026. 96 funds tracked by Wall St. Rank hold BDTX as of Q2 2026.

  • Dmitry Balyasny held 542,172 shares of Black Diamond Therapeutics worth $1M as of Q2 2026.
  • Dmitry Balyasny bought 31,361 Black Diamond Therapeutics shares in Q2 2026, an estimated $76.7K.
  • Black Diamond Therapeutics made up ﹤0.01% of Dmitry Balyasny's portfolio in Q2 2026, its #2207 holding.
  • Dmitry Balyasny first reported a position in Black Diamond Therapeutics in Q1 2021 and has held it in 4 quarters since.
  • Dmitry Balyasny's Black Diamond Therapeutics position peaked at $1.09M in Q1 2026.
  • 96 funds tracked by Wall St. Rank held Black Diamond Therapeutics as of Q2 2026.

Based on Balyasny Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.